Compare Agnico Eagle Mines Ltd (AEM) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Agnico Eagle Mines Ltd vs Recursion Pharmaceuticals Inc — how do they compare? Agnico Eagle Mines Ltd trades at $143.11 (market cap $75.10B), while Recursion Pharmaceuticals Inc trades at $3.67 (market cap $2.04B). The key difference: Agnico Eagle Mines Ltd is far larger — about 36.8× Recursion Pharmaceuticals Inc's market cap, and Agnico Eagle Mines Ltd pays a 1.2% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AEM | RXRX | |
|---|---|---|
Market Cap | $75.10B | $2.04B |
Sector | Basic Materials | Health |
52-Week High | $252.19 | $6.79 |
52-Week Low | $116.14 | $2.84 |
Enterprise Value | $72.30B | $1.46B |
Dividend Yield | 1.2% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Agnico Eagle Mines (AEM) trades at $150.33, down 2.29% amid a bearish technical signal but maintains strong fundamentals with a 14.59 P/E ratio and 39.46% net margin. Recent quarterly earnings consistently beat estimates, including Q1 2026 EPS of $3.40 versus $3.19 expected. Revenue grew to $11.91B in 2025, while news highlights temporary mining suspension at Barnat pit but affirms long-term growth projects.
Outlook remains positive with a $222.40 analyst consensus target, though risks include operational disruptions and gold price volatility. The stock offers value with robust cash flow and 67.74% buy ratings, but investors should monitor execution of expansion plans amid bearish technical indicators.
RXRX trades at $3.96, up 4.21% today, with a bullish technical signal from moving averages despite overbought RSI readings. The company shows improving quarterly EPS beats but faces deep losses with a -851.51% net margin. Recent news highlights its AI-driven drug discovery platform and inclusion in Cathie Wood's portfolio (The Motley Fool, 2026-07-05).
Analyst consensus is mixed with 40% buy ratings and a $7.83 price target suggesting significant upside, but high cash burn and negative profitability pose substantial risks. Investment appeal hinges on successful clinical advancements offsetting current financial challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agnico Eagle Mines Ltd
Agnico Eagle Mines is a gold miner operating mines in Canada, Mexico, and Finland. It also owns 50% of the Canadian Malartic mine. Agnico operated just one mine, LaRonde, as recently as 2008 before bringing its other mines on line in rapid succession in the following years. The company produced more than 1.7 million gold ounces in 2020. Agnico Eagle is focused on increasing gold production in lower-risk jurisdictions.
Read more on AEM →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
